{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T18:31:07Z","timestamp":1794508267627,"version":"4.9.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008723","name":"Suomen L\u00e4\u00e4ketieteen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Research Council of Finland","doi-asserted-by":"publisher","award":["339900"],"award-info":[{"award-number":["339900"]}],"id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>In subjects with cardiovascular disease (CVD), higher N-terminal proatrial natriuretic peptide (NT-proANP) are associated with major cardiovascular outcomes, while in subjects without CVDs longitudinal data is largely lacking. Our aim was to assess cross-sectional associations between NT-proANP and key CVD factors (1044 subjects, 40\u201362 years, 51% hypertensive, 49% males) and to evaluate the predictive potential of NT-proANP for HF events, CVD events, CVD mortality, and total mortality over an up-to 31-year follow-up period. In subjects with CVDs, the high NT-proANP tertile had decreased kidney function, higher prevalence of CVDs and adverse echocardiographic measures but also the lowest fasting insulin levels, and in longitudinal analysis had an increased risk for HF events and CVD mortality. In subjects without CVDs the high NT-proANP tertile had the healthiest metabolic profile with the lowest BMI, fasting insulin levels and blood pressure, and in longitudinal analysis weaker evidence for increased risk for HF events and CVD mortality were observed. Regardless of CVDs, NT-proANP levels increased with age and were not independently associated with total mortality. In this middle-aged population, followed for up to three decades, the cross-sectional and longitudinal associations of NT-proANP levels were largely dependent on population characteristics such as age and CVDs.<\/jats:p>","DOI":"10.1038\/s41598-025-03819-6","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:58:34Z","timestamp":1748429914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prognostic value of NT-proANP levels on major cardiovascular outcomes in a 31-year follow-up study depends on baseline morbidity"],"prefix":"10.1038","volume":"15","author":[{"given":"Samuli","family":"Sakko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Perki\u00f6m\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Ylitalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Huikuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olavi","family":"Ukkola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peppi","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joona","family":"Tapio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"3819_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.peptides.2018.08.006","volume":"111","author":"A Matsuo","year":"2019","unstructured":"Matsuo, A., Nagai-Okatani, C., Nishigori, M., Kangawa, K. & Minamino, N. Natriuretic peptides in human heart: novel insight into their molecular forms, functions, and diagnostic use. Peptides (N Y). 111, 3\u201317 (2019).","journal-title":"Peptides (N Y)"},{"key":"3819_CR2","doi-asserted-by":"crossref","unstructured":"Yagmur, E. et al. Elevated MR-proANP plasma concentrations are associated with sepsis and predict mortality in critically ill patients. J. Transl. Med. 17, (2019).","DOI":"10.1186\/s12967-019-02165-2"},{"key":"3819_CR3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","volume":"17","author":"JP Goetze","year":"2020","unstructured":"Goetze, J. P. et al. Cardiac natriuretic peptides. Nat. Rev. Cardiol. 17, 698\u2013717 (2020).","journal-title":"Nat. Rev. Cardiol."},{"key":"3819_CR4","unstructured":"McDonagh, T. A. et al. Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 44, 3627\u20133639 (2023)."},{"key":"3819_CR5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/01.CIR.93.11.1963","volume":"93","author":"T Omland","year":"1996","unstructured":"Omland, T. et al. Plasma brain natriuretic peptide as an Indicator of left ventricular systolic function and Long-term survival after acute myocardial infarction. Circulation. 93, 1963\u20131969 (1996).","journal-title":"Circulation"},{"key":"3819_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0008-6363(01)00195-X","volume":"51","author":"F Boomsma","year":"2001","unstructured":"Boomsma, F. & van den Meiracker, A. H. Plasma A-and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc. Res. 51, 442\u2013449 (2001).","journal-title":"Cardiovasc. Res."},{"key":"3819_CR7","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1161\/01.CIR.90.1.195","volume":"90","author":"H Yasue","year":"1994","unstructured":"Yasue, H. et al. Localization and mechanism of secretion of B-Type natriuretic peptide in comparison with those of A-Type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90, 195\u2013203 (1994).","journal-title":"Circulation"},{"key":"3819_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMoa031994","volume":"7","author":"TJ Wang","year":"2004","unstructured":"Wang, T. J. et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med. 7, 655\u2013663 (2004).","journal-title":"N. Engl. J. Med."},{"key":"3819_CR9","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.4065\/mcp.2011.0437","volume":"86","author":"PM McKie","year":"2011","unstructured":"McKie, P. M. et al. Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: A 9-year follow-up study. Mayo Clin. Proc. 86, 1154\u20131160 (2011).","journal-title":"Mayo Clin. Proc."},{"key":"3819_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/eurheartj\/ehi878","volume":"27","author":"JA Laukkanen","year":"2006","unstructured":"Laukkanen, J. A. et al. Plasma N-terminal fragments of natriuretic propeptides predict the risk of cardiovascular events and mortality in middle-aged men. Eur. Heart J. 27, 1230\u20131237 (2006).","journal-title":"Eur. Heart J."},{"key":"3819_CR11","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1016\/j.hrthm.2018.03.021","volume":"15","author":"P B\u00fcttner","year":"2018","unstructured":"B\u00fcttner, P. et al. Role of NT-proANP and NT-proBNP in patients with atrial fibrillation: association with atrial fibrillation progression phenotypes. Heart Rhythm. 15, 1132\u20131137 (2018).","journal-title":"Heart Rhythm"},{"key":"3819_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1365-2796.1997.128149000.x","volume":"241","author":"T Wall\u00e9n","year":"1997","unstructured":"Wall\u00e9n, T. et al. Atrial natriuretic peptides predict mortality in the elderly. J. Intern. Med. 241, 269\u2013275 (1997).","journal-title":"J. Intern. Med."},{"key":"3819_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1042\/CS20040087","volume":"107","author":"IB Squire","year":"2004","unstructured":"Squire, I. B., O\u2019Brien, R. J., Demme, B., Davies, J. E. & Ng, L. L. N-terminal pro-atrial natriuretic peptide (N-ANP) and N-terminal pro-B-type natriuretic peptide (N-BNP) in the prediction of death and heart failure in unselected patients following acute myocardial infarction. Clin. Sci. (Lond.). 107, 309\u2013316 (2004).","journal-title":"Clin. Sci. (Lond)"},{"key":"3819_CR14","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1161\/CIRCULATIONAHA.114.009273","volume":"130","author":"V Xanthakis","year":"2014","unstructured":"Xanthakis, V. et al. Ideal cardiovascular health associations with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in the Framingham offspring study. Circulation 130, 1676\u20131683 (2014).","journal-title":"Circulation"},{"key":"3819_CR15","doi-asserted-by":"crossref","unstructured":"Kerkel\u00e4, R., Ulvila, J. & Magga, J. Natriuretic peptides in the regulation of cardiovascular physiology and metabolic events. J. Am. Heart Assoc. 4, (2015).","DOI":"10.1161\/JAHA.115.002423"},{"key":"3819_CR16","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1161\/CIRCULATIONAHA.106.655142","volume":"115","author":"TJ Wang","year":"2007","unstructured":"Wang, T. J. et al. Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 115, 1345\u20131353 (2007).","journal-title":"Circulation"},{"key":"3819_CR17","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.1210\/jc.2011-1182","volume":"96","author":"AM Khan","year":"2011","unstructured":"Khan, A. M. et al. Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J. Clin. Endocrinol. Metab. 96, 3242\u20133249 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3819_CR18","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jacc.2013.03.038","volume":"62","author":"IJ Neeland","year":"2013","unstructured":"Neeland, I. J. et al. Higher natriuretic peptide levels associate with a favorable adipose tissue distribution profile. J. Am. Coll. Cardiol. 62, 752\u2013760 (2013).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3819_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1210\/jc.2011-2425","volume":"97","author":"M Magnusson","year":"2012","unstructured":"Magnusson, M. et al. Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malm\u00f6 diet and cancer study. J. Clin. Endocrinol. Metab. 97, 638\u2013645 (2012).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3819_CR20","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.2337\/dc21-0811","volume":"44","author":"C Sujana","year":"2021","unstructured":"Sujana, C. et al. Natriuretic peptides and risk of type 2 diabetes: results from the biomarkers for cardiovascular risk assessment in Europe (BiomarCaRE) consortium. Diabetes Care. 44, 2527\u20132535 (2021).","journal-title":"Diabetes Care"},{"key":"3819_CR21","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1210\/jc.2015-3518","volume":"101","author":"A Juji\u0107","year":"2016","unstructured":"Juji\u0107, A. et al. Atrial natriuretic peptide in the high normal range is associated with lower prevalence of insulin resistance. J. Clin. Endocrinol. Metab. 101, 1372\u20131380 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3819_CR22","doi-asserted-by":"crossref","unstructured":"Juji\u0107, A. et al. Atrial natriuretic peptide and type 2 diabetes development\u2014Biomarker and genotype association study. PLoS One. 9, (2014).","DOI":"10.1371\/journal.pone.0089201"},{"key":"3819_CR23","doi-asserted-by":"crossref","unstructured":"Pfister, R. et al. Mendelian randomization study of B-type natriuretic peptide and type 2 diabetes: evidence of causal association from population studies. PLoS Med. 8, (2011).","DOI":"10.1371\/journal.pmed.1001112"},{"key":"3819_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1046\/j.1365-2796.1999.00429.x","volume":"245","author":"AO Rantala","year":"1999","unstructured":"Rantala, A. O. et al. Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J. Intern. Med. 245, 163\u2013174 (1999).","journal-title":"J. Intern. Med."},{"key":"3819_CR25","doi-asserted-by":"crossref","unstructured":"P\u00f6ykk\u00f6, S. M. et al. Low plasma Ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes. 52, (2003).","DOI":"10.2337\/diabetes.52.10.2546"},{"key":"3819_CR26","doi-asserted-by":"crossref","unstructured":"Alberti, K. G. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. (1998).","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S"},{"key":"3819_CR27","doi-asserted-by":"crossref","unstructured":"Tapio, J., V\u00e4h\u00e4nikkil\u00e4, H., Kes\u00e4niemi, Y. A., Ukkola, O. & Koivunen, P. Higher hemoglobin levels are an independent risk factor for adverse metabolism and higher mortality in a 20-year follow-up. Sci. Rep. 11, (2021).","DOI":"10.1038\/s41598-021-99217-9"},{"key":"3819_CR28","first-page":"R647","volume":"263","author":"O Vuolteenaho","year":"1992","unstructured":"Vuolteenaho, O., Koistinen, P., Martikkala, V., Takala, T. & Leppiluoto, J. Effect of physical exercise in hypobaric conditions on atrial natriuretic peptide secretion. Am. J. Physiol. 263, R647\u2013R652 (1992).","journal-title":"Am. J. Physiol."},{"key":"3819_CR29","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker, L. A. et al. Estimating glomerular filtration rate from serum creatinine and Cystatin C. N. Engl. J. Med. 367, 20\u201329 (2012).","journal-title":"N. Engl. J. Med."},{"key":"3819_CR30","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1161\/01.HYP.35.3.844","volume":"35","author":"P Verdecchia","year":"2000","unstructured":"Verdecchia, P. Prognostic value of ambulatory blood pressure current evidence and clinical implications. Hypertension. 35, 844\u2013851 (2000).","journal-title":"Hypertension"},{"key":"3819_CR31","unstructured":"Ylitalo, A. Cardiovascular autonomic regulation in systemic hypertension. Doctoral dissertation, University of Oulu, Acta Universitatis Ouluensis, D, Medica. (1999)."},{"key":"3819_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.echo.2014.10.003","volume":"28","author":"RM Lang","year":"2015","unstructured":"Lang, R. M. et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J. Am. Soc. Echocardiogr. 28, 1\u201339e14 (2015).","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"3819_CR33","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1161\/01.CIR.45.3.602","volume":"45","author":"BL Troy","year":"1972","unstructured":"Troy, B. L., Pombo, J. & Rackley, C. E. Measurement of left ventricular wall thickness and mass by eehocardiography. Circulation 45, 602\u2013611 (1972).","journal-title":"Circulation"},{"key":"3819_CR34","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1586\/17474124.2015.1007955","volume":"9","author":"S Ballestri","year":"2015","unstructured":"Ballestri, S., Romagnoli, D., Nascimbeni, F., Francica, G. & Lonardo, A. Role of ultrasound in the diagnosis and treatment of nonalcoholic fatty liver disease and its complications. Expert Rev. Gastroenterol. Hepatol. 9, 603\u2013627 (2015).","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"3819_CR35","doi-asserted-by":"crossref","unstructured":"Suutari-J\u00e4\u00e4sk\u00f6, A. et al. Leisure time and occupational physical activity, overall and cardiovascular mortality: a 24-year follow-up in the OPERA study. Ann. Med 55, (2023).","DOI":"10.1080\/07853890.2023.2245429"},{"key":"3819_CR36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/S0002-9149(02)02464-5","volume":"90","author":"TJ Wang","year":"2002","unstructured":"Wang, T. J. et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 90, 254\u2013258 (2002).","journal-title":"Am. J. Cardiol."},{"key":"3819_CR37","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1016\/S0735-1097(98)00478-1","volume":"32","author":"A Luchner","year":"1998","unstructured":"Luchner, A. et al. Augmentation of the cardiac natriuretic peptides by Beta-Receptor antagonism: evidence from a population-based study. J. Am. Coll. Cardiol. 32, 1839\u20131883 (1998).","journal-title":"J. Am. Coll. Cardiol."},{"key":"3819_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1080\/00365510050184976","volume":"60","author":"H Holmstr\u00f6m","year":"2000","unstructured":"Holmstr\u00f6m, H. Plasma levels of N-terminal proatrial natriuretic peptide in children are dependent on renal function and age. Scand. J. Clin. Lab. Investig. 60, 149\u2013159 (2000).","journal-title":"Scand. J. Clin. Lab. Investig."},{"key":"3819_CR39","doi-asserted-by":"crossref","unstructured":"Couch, C. A., Fowler, L. A., Parcha, V., Arora, P. & Gower, B. A. Associations of atrial natriuretic peptide with measures of insulin and adipose depots. Physiol. Rep. 11, (2023).","DOI":"10.14814\/phy2.15625"},{"key":"3819_CR40","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","volume":"109","author":"TJ Wang","year":"2004","unstructured":"Wang, T. J. et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 109, 594\u2013600 (2004).","journal-title":"Circulation"},{"key":"3819_CR41","doi-asserted-by":"crossref","unstructured":"Choi, H. I. et al. Clinical medicine fatty liver is associated with low N-Terminal Pro-B-Type natriuretic peptide in a healthy population. J. Clin. Med. 10, (2021).","DOI":"10.3390\/jcm10071402"},{"key":"3819_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/ajcn\/77.1.43","volume":"77","author":"JM Schwarz","year":"2003","unstructured":"Schwarz, J. M., Linfoot, P., Dare, D. & Aghajanian, K. Hepatic de Novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. Am. J. Clin. Nutr. 77, 43\u201350 (2003).","journal-title":"Am. J. Clin. Nutr."},{"key":"3819_CR43","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1161\/CIRCULATIONAHA.105.567727","volume":"113","author":"ME Davis","year":"2006","unstructured":"Davis, M. E. et al. Introduction of Metoprolol increases plasma B-type cardiac natriuretic peptides in mild, stable heart failure. Circulation 113, 977\u2013985 (2006).","journal-title":"Circulation"},{"key":"3819_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1067\/mhj.2001.117131","volume":"142","author":"W Qi","year":"2001","unstructured":"Qi, W. et al. Natriuretic peptides in patients with aortic stenosis. Am. Heart J. 142, 725\u2013732 (2001).","journal-title":"Am. Heart J."},{"key":"3819_CR45","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1161\/HYPERTENSIONAHA.107.097634","volume":"50","author":"D Conen","year":"2007","unstructured":"Conen, D., Glynn, R. J., Buring, J. E., Ridker, P. M. & Zee, R. Y. L. Natriuretic peptide precursor A gene polymorphisms and risk of blood pressure progression and incident hypertension. Hypertension. 50, 1114\u20131119 (2007).","journal-title":"Hypertension"},{"key":"3819_CR46","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1093\/ajh\/hpaa224","volume":"34","author":"CD Nicoli","year":"2021","unstructured":"Nicoli, C. D. et al. N-terminal pro-b-type natriuretic peptide and longitudinal risk of hypertension. Am. J. Hypertens. 34, 476\u2013483 (2021).","journal-title":"Am. J. Hypertens."},{"key":"3819_CR47","doi-asserted-by":"crossref","unstructured":"Seew\u00f6ster, T. et al. Association between cardiovascular magnetic resonance-derived left atrial dimensions, electroanatomical substrate and NT-proANP levels in atrial fibrillation. J. Am. Heart Assoc. 7, (2018).","DOI":"10.1161\/JAHA.118.009427"},{"key":"3819_CR48","doi-asserted-by":"publisher","first-page":"997","DOI":"10.6061\/clinics\/2013(07)18","volume":"68","author":"A Bacaksiz","year":"2013","unstructured":"Bacaksiz, A. et al. Assessment of the left atrial volume index and plasma NT-proANP level in patients with acute ST-elevation myocardial infarction. Clinics. 68, 997\u20131003 (2013).","journal-title":"Clinics"},{"key":"3819_CR49","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/oxfordjournals.eurheartj.a014753","volume":"17","author":"CM Yu","year":"1996","unstructured":"Yu, C. M. et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure higher ANP and BNP levels are associated with the restrictive filling pattern. Eur. Heart J. 17, 1694\u20131702 (1996).","journal-title":"Eur. Heart J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03819-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03819-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T10:58:41Z","timestamp":1748429921000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-03819-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3819"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-03819-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18660"}}